-+ 0.00%
-+ 0.00%
-+ 0.00%

INNOVENT ANNOUNCES FIRST PARTICIPANT DOSED OF IBI128 (TIGULIXOSTAT, XOI) IN PHASE 3 CLINICAL STUDY

Reuters·03/23/2026 00:00:00

Please log in to view news